In the Diabetes Prevention Program Outcomes Study (DPPOS), 2,266 adults with prediabetes or diabetes mellitus (DM) showed that higher fasting insulin and HOMA-IR were linked to worse ECG-based autonomic function, including lower HRV and higher resting heart rate. The signal was especially notable in women: each SD increase in HbA1c was tied to lower rMSSD (β -0.08, 95% CI -0.14 to -0.03) and lower SDNN (β -0.08, 95% CI -0.12 to -0.03), while HOMA-IR tracked with lower rMSSD in both men (β -0.11) and women (β -0.07).

Why It Matters To Your Practice

• NPs and PAs are often the first clinicians to spot subtle cardiometabolic decline, and this study reinforces that frontline judgment: worsening insulin resistance may be showing up in autonomic function before overt cardiovascular events.

• For patients with prediabetes or DM, higher glycemic burden was not just a lab issue — it correlated with higher resting heart rate and lower HRV, both meaningful physiologic clues during routine follow-up.

• Sex-specific differences matter: associations between HbA1c/FPG and lower HRV were clearer in women, underscoring the value of tailored risk conversations rather than one-size-fits-all counseling.

Clinical Benefits

• This gives you another practical reason to push early lifestyle and metabolic interventions when fasting insulin or HOMA-IR are worsening, even if the patient feels well.

• Resting heart rate trends, ECG data, and glycemic markers together can help sharpen your assessment of cardiometabolic risk in primary care and endocrine follow-up.

• Your continuity with patients puts you in the best position to connect rising HbA1c, fasting glucose, or insulin resistance with broader physiologic stress — and to act before complications stack up.

Managing Risks

• This was a cross-sectional analysis, so it shows association, not causation; lower HRV should not be interpreted as proof that dysglycemia directly caused autonomic dysfunction.

• The cohort was older on average (mean age 65 years) and already had prediabetes or diabetes, so generalizability to younger or lower-risk populations may be limited.

• HRV is influenced by medications, fitness, sleep, and comorbidities, so use these findings to inform clinical context — not to overcall risk based on a single metric.

The Bottom Line

• In DPPOS, higher insulin resistance and worse glycemic markers were linked to poorer cardiac autonomic measures, including lower HRV and higher resting heart rate.

• For NPs and PAs, this is squarely in your lane: you are not “backup” to anyone when it comes to recognizing early metabolic deterioration and translating it into timely, patient-centered action.

• If insulin resistance is rising, consider it a cue to intensify risk-factor management, reinforce adherence, and watch for broader cardiometabolic consequences.